The HIV prevention shot, lenacapavir, will be rolled out at South African clinics within the next couple of months and from 2027, the health department will also buy generics. But how best to spend the HIV prevention budget so that the country can drive infections down as fast as possible? We take a look at what the modelling data shows
Who should get what slice of the pie once the medicine is available in public clinics? And are numbers alone what would drive decisions?
None of the companies that will be involved have a licence from the inventor of Lenacapavir, Gilead Sciences, to make the jab
The country’s medicines regulator Sahpra says it’s on track to announce its registration decision by the end of October
The shot, called Lenacapavir, has a 100% success rate in preventing young women from getting HIV through sex